Tradestie Institutional Equity Comparison Engine
CDNA vs IMDX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CDNA Overall Edge
CDNA Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CareDx, Inc. (CDNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CDNA trades at 46.0x Forward P/E with 1.6% operating margin (+39.3% YoY revenue) versus IMDX at N/M Forward P/E and -1883.2% operating margin (+115.0% YoY). In options structure, CDNA sits in CONSOLIDATION (34th %ile IV; Dealer Gamma Walls on Pro) against IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CDNA
CDNA 46.0x vs IMDX N/M Fwd P/E
Growth & Margin Winner
CDNA
Op Margin 1.6% vs -1883.2% ยท YoY +39.3% vs +115.0%
Momentum & Technical Winner
CDNA
1Y +356.4% vs -73.8% ยท 52W Pos 75% vs 3%
Options & Structure Winner
CDNA
CONSOLIDATION (34th %ile IV) vs BREAKDOWN (12th %ile IV)
CDNA
NASDAQ
CareDx, Inc.
Services-Medical Laboratories
$71.92
-3.39% 1D
Market Cap
$3.9B
1M Return
+1.67%
1Y Return
+356.35%
Forward P/E
46.0x
Unified AI Score
32.0 / 100
SELL
Tech 31.0
Fund 48.0
Flow 70.0
Mom 36.0
IMDX
NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap
$52.1M
1M Return
-45.03%
1Y Return
-73.78%
Forward P/E
N/M
Unified AI Score
45.5 / 100
HOLD
Tech 50.0
Fund 40.0
Flow 58.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CDNA +356.35%
IMDX -73.78%
Spread: +430.13 pp (CDNA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CDNA Revenue | IMDX Revenue | CDNA Op. Margin | IMDX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $80M | N/A | -20.3% | N/A | CDNA |
| FY2019 | $130M | N/A | -19.3% | N/A | CDNA |
| FY2020 | $190M | $0M | -11.7% | -2443.3% | CDNA |
| FY2021 | $300M | $0M | -10.0% | -2444.3% | CDNA |
| FY2022 | $320M | $0M | -24.0% | -1878.6% | CDNA |
| FY2023 | $280M | $0M | -72.5% | -1672.4% | CDNA |
| FY2024 | $330M | $0M | 12.2% | -3245.1% | CDNA |
| FY2025 | $380M | $0M | -8.1% | -1260.8% | CDNA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CDNA | IMDX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.9B | $52.1M | Larger Scale | CDNA |
| Trailing P/E Ratio Valuation | 31.5x | N/M | Lower Multiple | CDNA |
| Forward P/E Ratio Valuation | 46.0x | N/M | Lower Multiple | CDNA |
| Revenue Growth (YoY) Growth | +39.3% | +115.0% | Higher Growth | IMDX |
| Operating Margin (TTM) Profitability | 1.6% | -1883.2% | Higher Margin | CDNA |
| Net Profit Margin Profitability | 25.9% | 0.0% | Higher Margin | CDNA |
| Return on Equity (ROE) Capital Efficiency | 33.0% | -23603.1% | Higher ROE | CDNA |
| 52-Week Range Position Momentum | 75% ($15โ$91) | 3% ($2โ$8) | Stronger Trend | CDNA |
| Beta / 30D Volatility Risk Regime | 1.22ฮฒ ยท 97% Vol | 2.91ฮฒ ยท 76% Vol | Lower Realized Risk | IMDX |
| Unified Institutional Score Composite Signal | 32.0 / 100 (SELL) | 45.5 / 100 (HOLD) | Higher Composite | IMDX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CDNA vs IMDX Buy Guide
CDNA
CONSOLIDATION
33d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
34th %ile
IV Regime
Balanced (25thโ60th %ile)
IMDX
BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CDNA nor IMDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.